~~<i id='A10A951991'><strike id='A10A951991'><tt id='A10A951991'><pre id='A10A951991'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

knowledge

author：comprehensive 2025-10-02 22:23:54 - browse：15563

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Biogen walks away from Aduhelm, years after polarizing approval

leisure time

focus

leisure time

focus

hotspot

Fromlefttoright,toprow:STAT'sUshaLeeMcFarling;Vanderbilt'sConsueloWilkins;CarolinaReyesofUCDavisHeal

WSS

10 reasons why health care startups fail

Acelyrin, a rare IPO success, stumbles in its first big test

Vertex non

Regeneron agrees to White House price limits on anti

Why you shouldn’t ask, “What country has the best health care?”

FDA proposes changes to key medical devices approval pathway

leisure time

knowledge

leisure time

Sports medicine is finally prioritizing gender equality

IRA could hurt research into orphan drugs for rare diseases

Cancer drug shortages should be causing more outrage

Telehealth for opioid use disorder is lifesaving

Trump demands the U.S. pay no more for drugs than other countries … again

White House touts steps to stem shortages of cancer treatments

Moonlake's readout produced a cash windfall. Risks remain

White House pharmacy plagued with problems, investigation finds

Drug repurposing or repositioning? The language matters

Venture capital firm's plans to take over Akron hospital face hurdles

focus

Investment in vaccine development is lagging, report finds

New weight loss drugs vying to be the next Wegovy or Mounjaro

Merck, Johnson & Johnson CEOs will testify on high drug prices

Telehealth for opioid use disorder is lifesaving

Boston competes with Raleigh

Venture capital firm's plans to take over Akron hospital face hurdles

leisure time

focus

hotspot

hotspot